Compare Lemonade Inc (LMND) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Lemonade Inc trades at $46.42 (market cap $3.63B), while Vertex Pharmaceuticals Incorporated trades at $511.7 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 35.1× Lemonade Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| LMND | VRTX | |
|---|---|---|
Market Cap | $3.63B | $127.55B |
Volume | 1,544,794 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $96.57 | $557.96 |
52-Week Low | $43.91 | $407.37 |
Typical Hold Time | 27 Days | 120 Days |
Enterprise Value | $3.49B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LMND trades at $46.64, down 0.41% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains strong at 32% year-over-year in Q2 2026, with improving loss ratios and gross profit up 76%. The company is expanding geographically and expects its first EBITDA-positive quarter in late 2026, supported by AI-driven efficiency gains.
While LMND shows promising growth and path to profitability, the stock faces headwinds from persistent net losses, high valuation multiples, and mixed analyst sentiment. The consensus price target of $67.00 suggests 44% upside potential, but investors must weigh growth prospects against ongoing cash burn and competitive pressures in the insurtech space.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
